CA2357735A1 - Modulation of immune response by ribavirin - Google Patents

Modulation of immune response by ribavirin Download PDF

Info

Publication number
CA2357735A1
CA2357735A1 CA002357735A CA2357735A CA2357735A1 CA 2357735 A1 CA2357735 A1 CA 2357735A1 CA 002357735 A CA002357735 A CA 002357735A CA 2357735 A CA2357735 A CA 2357735A CA 2357735 A1 CA2357735 A1 CA 2357735A1
Authority
CA
Canada
Prior art keywords
challenge
nucleoside
ribavirin
cells
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002357735A
Other languages
English (en)
French (fr)
Inventor
Robert Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Pharmaceuticals International Inc USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2357735A1 publication Critical patent/CA2357735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002357735A 1999-01-29 1999-12-20 Modulation of immune response by ribavirin Abandoned CA2357735A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24136799A 1999-01-29 1999-01-29
US09/241,367 1999-01-29
PCT/US1999/030490 WO2000044388A1 (en) 1999-01-29 1999-12-20 Modulation of immune response by ribavirin

Publications (1)

Publication Number Publication Date
CA2357735A1 true CA2357735A1 (en) 2000-08-03

Family

ID=22910442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002357735A Abandoned CA2357735A1 (en) 1999-01-29 1999-12-20 Modulation of immune response by ribavirin

Country Status (20)

Country Link
EP (1) EP1146883A4 (xx)
JP (1) JP2002535371A (xx)
KR (1) KR20020023939A (xx)
CN (1) CN1334736A (xx)
AU (1) AU2483300A (xx)
BR (1) BR9917090A (xx)
CA (1) CA2357735A1 (xx)
CZ (1) CZ20012519A3 (xx)
HK (1) HK1040937A1 (xx)
HR (1) HRP20010496A2 (xx)
HU (1) HUP0200027A2 (xx)
IL (1) IL144130A0 (xx)
MX (1) MXPA01007211A (xx)
NO (1) NO20013529L (xx)
PL (1) PL364699A1 (xx)
RU (1) RU2211698C2 (xx)
SI (1) SI20802A (xx)
SK (1) SK10092001A3 (xx)
WO (1) WO2000044388A1 (xx)
ZA (1) ZA200105595B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002014362A2 (en) 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2006339963B2 (en) * 2006-03-14 2010-02-25 Wholesome Biopharm Pty Ltd Method and composition for treating allergic diseases
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (en) * 1980-04-17 1981-10-28 Beecham Group Plc Virazole derivatives, process for their preparation and use as antiviral agents
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
EP0262125B1 (en) * 1986-03-27 1996-03-27 Gensia, Inc. AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
BR9707154A (pt) * 1996-01-23 1999-05-25 Icn Pharmaceuticals Modulaç o da express o de citocina em th1/th2 por ribavirina e análogos de ribavirina em linfócitos t ativados
SK284054B6 (sk) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
HUP0200027A2 (en) 2002-04-29
BR9917090A (pt) 2001-10-16
CN1334736A (zh) 2002-02-06
WO2000044388A1 (en) 2000-08-03
RU2211698C2 (ru) 2003-09-10
NO20013529D0 (no) 2001-07-17
SI20802A (sl) 2002-08-31
HK1040937A1 (zh) 2002-06-28
ZA200105595B (en) 2002-10-07
AU2483300A (en) 2000-08-18
CZ20012519A3 (cs) 2002-05-15
IL144130A0 (en) 2002-05-23
PL364699A1 (en) 2004-12-13
HRP20010496A2 (en) 2003-08-31
JP2002535371A (ja) 2002-10-22
EP1146883A1 (en) 2001-10-24
KR20020023939A (ko) 2002-03-29
SK10092001A3 (sk) 2002-02-05
EP1146883A4 (en) 2004-11-24
NO20013529L (no) 2001-09-12
MXPA01007211A (es) 2002-05-06

Similar Documents

Publication Publication Date Title
US6509320B1 (en) Purine L-nucleosides, analogs and uses thereof
US6455508B1 (en) Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
AU669702B2 (en) Enantiomeric hydroxylated xanthine compounds
CN100528173C (zh) 4′-取代的核苷
CN1286258A (zh) 嘌呤l－核苷、其类似物及其用途
US6423695B1 (en) Cytokine related treatments of disease
US20020187945A1 (en) Modulation of immune response by ribavirin
CA2357735A1 (en) Modulation of immune response by ribavirin
US7056895B2 (en) Tirazole nucleoside analogs and methods for using same
CN1312254A (zh) 新的核苷
WO2002085916A1 (en) 9-[(5-dihydroxyboryl)-pentyl] purines, inhibitor of inflammatory cytokines
US20090176721A1 (en) Nucleoside analogs with carboxamidine modified monocyclic base
NZ512879A (en) Modulation of immune response by Ribavirin
WO2013056510A1 (zh) 脱氧核苷与核苷组合在制备肿瘤药物中的应用
CN1447692A (zh) 药物释放至肝细胞和治疗黄病毒感染的方法
EP1132393A1 (en) L-Ribavirin and uses thereof
EP1072607A2 (en) Purine L-nucleosides, analogs and uses therof
Billiau Interferons: the pathways of discovery: II. Immunomodulatory, in vivo and applied aspects
WO2021239850A1 (fr) Utilisation de nmn pour reduire l'immunodepression et l'immunosenescence
AU751742B2 (en) Purine L-nucleosides, analogs and uses thereof
NZ505553A (en) 8-substituted alpha or beta L-guanosine analogs and uses thereof
CA2323791A1 (en) Purine l-nucleosides, analogs and uses thereof
CN1817349A (zh) 具有甲脒修饰的单环碱基的核苷类似物
EP1329220A1 (en) Cytokine related treatments of disease

Legal Events

Date Code Title Description
FZDE Discontinued